ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell ...

Preliminary Phase 2 data presented in November at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting showed that a combination of AU-007 and low-dose, subcutaneous aldesleukin is ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

Recently, the incidence of zoonoses has shown a global upward trend. There are more than 60 emerging infectious diseases and ...

A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute ...

Likewise, inflammatory diseases may benefit from the targeted action ... multi-specific antibodies in neurodegenerative diseases and viral infections, where intricate disease mechanisms ...

Please discuss the class and complete drug profile of amyloid-targeting therapies for Alzheimer disease, including their mechanisms of action, efficacy, and safety profiles.